<p>Ascendis Pharma A/S（纳斯达克代码：ASND - 获取免费报告）在周五的交易中创下了 52 周新高，此前 Stifel Nicolaus 将该股票的目标价从 254.00 美元上调至 256.00 美元。Stifel Nicolaus 目前对该股票给予买入评级。Ascendis Pharma A/S 的交易最高达到 229.94 美元，最后交易价格为 220.3560 美元，成交量为 1088268 股。该股票此前收盘价为 210.16 美元。</p>
<ul>
<li>BioMarin 股票能否满足华尔街的高期望？</li>
</ul>
<p>其他一些分析师也对该股票进行了评论。Raymond James Financial 在 10 月 17 日的研究报告中开始覆盖 Ascendis Pharma A/S 的股票。他们给予该公司的&#34;强力买入&#34;评级，并设定了 271.00 美元的目标价。Wall Street Zen 在 11 月 15 日的研究报告中将 Ascendis Pharma A/S 的评级从&#34;买入&#34;下调至&#34;持有&#34;。Weiss Ratings 在 10 月 8 日的报告中重申了对 Ascendis Pharma A/S 的&#34;卖出（d-）&#34;评级。Cantor Fitzgerald 在 11 月 26 日的研究报告中重新发布了对 Ascendis Pharma A/S 的&#34;增持&#34;评级。最后，Wolfe Research 在 11 月 18 日的研究报告中开始覆盖 Ascendis Pharma A/S。他们设定了&#34;同业表现&#34;评级和 255.00 美元的目标价。两位投资分析师给予该股票&#34;强力买入&#34;评级，十四位分析师给予&#34;买入&#34;评级，一位分析师给予&#34;卖出&#34;评级。根据 MarketBeat 的数据，该公司目前的共识评级为&#34;买入&#34;，共识目标价为 256.73 美元。</p>
<p>获取 <strong>Ascendis Pharma A/S</strong> 的提醒：</p>
<p><strong>查看我们对 ASND 的最新分析</strong></p>
<h2>机构资金流入和流出</h2>
<ul>
<li>3 只超卖股票具有大幅反弹潜力</li>
</ul>
<p>一些对冲基金和其他机构投资者最近买入和卖出了该股票的股份。Advisory Services Network LLC 在第三季度以 26,000 美元的估值收购了 Ascendis Pharma A/S 的新头寸。Compagnie Lombard Odier SCmA 在第二季度购买了 Ascendis Pharma A/S 的新股份，价值约 39,000 美元。Jones Financial Companies Lllp 在第三季度将其在 Ascendis Pharma A/S 的持股增加了 57.2%。Jones Financial Companies Lllp 现在拥有 228 股该生物技术公司的股票，价值 44,000 美元，此前在上个季度增持了 83 股。First Horizon Advisors Inc.在第二季度以约 41,000 美元的估值购买了 Ascendis Pharma A/S 的新股份。最后，Hantz Financial Services Inc.在第二季度将其在 Ascendis Pharma A/S 的持股增加了 291.1%。Hantz Financial Services Inc.现在拥有 352 股该生物技术公司的股票，价值 61,000 美元，此前在上个季度增持了 262 股。</p>
<h2>Ascendis Pharma A/S 股票表现</h2>
<p>该公司的 50 日移动平均线为 206.01 美元，200 日移动平均线为 190.73 美元。该股票的市值为 135.9 亿美元，市盈率为-49.63，贝塔值为 0.45。</p>
<p>Ascendis Pharma A/S（纳斯达克代码：ASND - 获取免费报告）最后一次公布季度财报是在 11 月 13 日。该生物技术公司报告每股收益（EPS）为（1.17 美元），低于共识预期的（0.41 美元）76 美分。该公司本季度的收入为 2.5071 亿美元，而共识预期为 2.4691 亿美元。作为一个整体，股票研究分析师预测 Ascendis Pharma A/S 在本年度将发布-4.34 的每股收益。</p>
<h2>关于 Ascendis Pharma A/S</h2>
<p>（获取免费报告）</p>
<p>Ascendis Pharma A/S 是一家生物制药公司，专注于开发满足未满足医疗需求的疗法。它提供 SKYTROFA 用于治疗生长激素缺乏症（GHD）患者。该公司还在临床开发中开发三种独立的内分泌罕见疾病产品候选药物，并专注于推进肿瘤治疗候选药物。</p>
<h2>阅读更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Ascendis Pharma A/S</li>
<li>多元化可以平滑回报并降低投资组合风险</li>
<li>CrowdStrike 股票即使在季度业绩大爆发后也无法反弹</li>
<li>如何计算通货膨胀率</li>
<li>Chewy 股票刚刚发出 2026 年的重大买入信号</li>
<li>纽约证券交易所的股票为投资者提供多种优质选择</li>
<li>博通在财报后下滑，即使人工智能需求激增</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Ascendis Pharma A/S 吗？</h2>
<p>在考虑 Ascendis Pharma A/S 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Ascendis Pharma A/S 并不在名单上。</p>
<p>虽然 Ascendis Pharma A/S 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Ascendis制药

<p>Ascendis Pharma A/S（纳斯达克代码：ASND）在 Stifel Nicolaus 将其目标价从 254.00 美元上调至 256.00 美元并维持买入评级后，达到了新的 52 周高点。该股最高交易价为 229.94 美元，收盘价为 220.3560 美元。其他分析师的评级各异，市场共识目标价为 256.73 美元。最近的机构投资包括 Advisory Services Network LLC 和 Compagnie Lombard Odier SCmA。该公司报告的季度收益为 2.5071 亿美元，未能达到市场共识预期</p>

<p>Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) hit a new 52-week high during trading on Friday after Stifel Nicolaus raised their price target on the stock from $254.00 to $256.00. Stifel Nicolaus currently has a buy rating on the stock. Ascendis Pharma A/S traded as high as $229.94 and last traded at $220.3560, with a volume of 1088268 shares trading hands. The stock had previously closed at $210.16.</p>
<div class="lb-trans"><p>Ascendis Pharma A/S（纳斯达克代码：ASND - 获取免费报告）在周五的交易中创下了 52 周新高，此前 Stifel Nicolaus 将该股票的目标价从 254.00 美元上调至 256.00 美元。Stifel Nicolaus 目前对该股票给予买入评级。Ascendis Pharma A/S 的交易最高达到 229.94 美元，最后交易价格为 220.3560 美元，成交量为 1088268 股。该股票此前收盘价为 210.16 美元。</p>
</div><ul>
<li>Can BioMarin Stock Live Up to Wall Street’s High Expectations?</li>
</ul>
<div class="lb-trans"><ul>
<li>BioMarin 股票能否满足华尔街的高期望？</li>
</ul>
</div><p>A number of other analysts have also commented on the stock. Raymond James Financial started coverage on shares of Ascendis Pharma A/S in a research note on Friday, October 17th. They issued a &#34;strong-buy&#34; rating and a $271.00 price target for the company. Wall Street Zen lowered Ascendis Pharma A/S from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 15th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Ascendis Pharma A/S in a report on Wednesday, October 8th. Cantor Fitzgerald reissued an &#34;overweight&#34; rating on shares of Ascendis Pharma A/S in a research note on Wednesday, November 26th. Finally, Wolfe Research started coverage on Ascendis Pharma A/S in a research note on Tuesday, November 18th. They set a &#34;peer perform&#34; rating and a $255.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of &#34;Buy&#34; and a consensus target price of $256.73.</p>
<div class="lb-trans"><p>其他一些分析师也对该股票进行了评论。Raymond James Financial 在 10 月 17 日的研究报告中开始覆盖 Ascendis Pharma A/S 的股票。他们给予该公司的&#34;强力买入&#34;评级，并设定了 271.00 美元的目标价。Wall Street Zen 在 11 月 15 日的研究报告中将 Ascendis Pharma A/S 的评级从&#34;买入&#34;下调至&#34;持有&#34;。Weiss Ratings 在 10 月 8 日的报告中重申了对 Ascendis Pharma A/S 的&#34;卖出（d-）&#34;评级。Cantor Fitzgerald 在 11 月 26 日的研究报告中重新发布了对 Ascendis Pharma A/S 的&#34;增持&#34;评级。最后，Wolfe Research 在 11 月 18 日的研究报告中开始覆盖 Ascendis Pharma A/S。他们设定了&#34;同业表现&#34;评级和 255.00 美元的目标价。两位投资分析师给予该股票&#34;强力买入&#34;评级，十四位分析师给予&#34;买入&#34;评级，一位分析师给予&#34;卖出&#34;评级。根据 MarketBeat 的数据，该公司目前的共识评级为&#34;买入&#34;，共识目标价为 256.73 美元。</p>
</div><p>Get <strong>Ascendis Pharma A/S</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Ascendis Pharma A/S</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Analysis on ASND</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ASND 的最新分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><ul>
<li>3 Oversold Stocks with Big RSI Rebound Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只超卖股票具有大幅反弹潜力</li>
</ul>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Advisory Services Network LLC acquired a new position in Ascendis Pharma A/S in the 3rd quarter valued at $26,000. Compagnie Lombard Odier SCmA purchased a new stake in Ascendis Pharma A/S during the 2nd quarter worth approximately $39,000. Jones Financial Companies Lllp grew its holdings in Ascendis Pharma A/S by 57.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company's stock worth $44,000 after acquiring an additional 83 shares in the last quarter. First Horizon Advisors Inc. purchased a new stake in Ascendis Pharma A/S during the second quarter worth approximately $41,000. Finally, Hantz Financial Services Inc. lifted its stake in Ascendis Pharma A/S by 291.1% in the second quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company's stock valued at $61,000 after buying an additional 262 shares during the last quarter.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近买入和卖出了该股票的股份。Advisory Services Network LLC 在第三季度以 26,000 美元的估值收购了 Ascendis Pharma A/S 的新头寸。Compagnie Lombard Odier SCmA 在第二季度购买了 Ascendis Pharma A/S 的新股份，价值约 39,000 美元。Jones Financial Companies Lllp 在第三季度将其在 Ascendis Pharma A/S 的持股增加了 57.2%。Jones Financial Companies Lllp 现在拥有 228 股该生物技术公司的股票，价值 44,000 美元，此前在上个季度增持了 83 股。First Horizon Advisors Inc.在第二季度以约 41,000 美元的估值购买了 Ascendis Pharma A/S 的新股份。最后，Hantz Financial Services Inc.在第二季度将其在 Ascendis Pharma A/S 的持股增加了 291.1%。Hantz Financial Services Inc.现在拥有 352 股该生物技术公司的股票，价值 61,000 美元，此前在上个季度增持了 262 股。</p>
</div><h2>Ascendis Pharma A/S Stock Performance</h2>
<div class="lb-trans"><h2>Ascendis Pharma A/S 股票表现</h2>
</div><p>The company has a 50-day moving average of $206.01 and a 200-day moving average of $190.73. The stock has a market cap of $13.59 billion, a price-to-earnings ratio of -49.63 and a beta of 0.45.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 206.01 美元，200 日移动平均线为 190.73 美元。该股票的市值为 135.9 亿美元，市盈率为-49.63，贝塔值为 0.45。</p>
</div><p>Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The business had revenue of $250.71 million for the quarter, compared to the consensus estimate of $246.91 million. As a group, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.</p>
<div class="lb-trans"><p>Ascendis Pharma A/S（纳斯达克代码：ASND - 获取免费报告）最后一次公布季度财报是在 11 月 13 日。该生物技术公司报告每股收益（EPS）为（1.17 美元），低于共识预期的（0.41 美元）76 美分。该公司本季度的收入为 2.5071 亿美元，而共识预期为 2.4691 亿美元。作为一个整体，股票研究分析师预测 Ascendis Pharma A/S 在本年度将发布-4.34 的每股收益。</p>
</div><h2>About Ascendis Pharma A/S</h2>
<div class="lb-trans"><h2>关于 Ascendis Pharma A/S</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.</p>
<div class="lb-trans"><p>Ascendis Pharma A/S 是一家生物制药公司，专注于开发满足未满足医疗需求的疗法。它提供 SKYTROFA 用于治疗生长激素缺乏症（GHD）患者。该公司还在临床开发中开发三种独立的内分泌罕见疾病产品候选药物，并专注于推进肿瘤治疗候选药物。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Ascendis Pharma A/S</li>
<li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li>
<li>CrowdStrike Stock Can't Catch a Break—Even After a Blowout Quarter</li>
<li>How to Calculate Inflation Rate</li>
<li>Chewy Stock Just Flashed a Major Buy Signal for 2026</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>Broadcom Slips Post-Earnings Even as AI Demand Goes Parabolic</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Ascendis Pharma A/S</li>
<li>多元化可以平滑回报并降低投资组合风险</li>
<li>CrowdStrike 股票即使在季度业绩大爆发后也无法反弹</li>
<li>如何计算通货膨胀率</li>
<li>Chewy 股票刚刚发出 2026 年的重大买入信号</li>
<li>纽约证券交易所的股票为投资者提供多种优质选择</li>
<li>博通在财报后下滑，即使人工智能需求激增</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ascendis Pharma A/S Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Ascendis Pharma A/S 吗？</h2>
</div><p>Before you consider Ascendis Pharma A/S, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ascendis Pharma A/S 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Ascendis Pharma A/S 并不在名单上。</p>
</div><p>While Ascendis Pharma A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ascendis Pharma A/S 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Ascendis Pharma A/S（NASDAQ:ASND）在分析师上调评级后创下新的 52 周高点